While the prevalence of anti-ZIKV IgM antibodies was highest in the 46–60 year age group, there were no significant discrepancy in anti-ZIKV IgM seropositivity rates across age groups, indicating that the risk of ZIKV infection is homologous across different age groups. The gene discussed is CD40LG; the disease is Zika virus infectious disease.